Baillie Gifford & Co. Reduces Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)

Baillie Gifford & Co. trimmed its stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) by 21.6% during the 2nd quarter, Holdings Channel.com reports. The fund owned 63,333 shares of the biopharmaceutical company’s stock after selling 17,483 shares during the quarter. Baillie Gifford & Co.’s holdings in Sage Therapeutics were worth $688,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in shares of Sage Therapeutics by 8.1% in the first quarter. Vanguard Group Inc. now owns 5,751,373 shares of the biopharmaceutical company’s stock worth $107,781,000 after purchasing an additional 432,013 shares during the last quarter. RTW Investments LP increased its position in shares of Sage Therapeutics by 0.9% in the fourth quarter. RTW Investments LP now owns 5,197,019 shares of the biopharmaceutical company’s stock valued at $112,619,000 after acquiring an additional 47,537 shares during the period. Bellevue Group AG raised its stake in shares of Sage Therapeutics by 27.1% during the first quarter. Bellevue Group AG now owns 4,465,544 shares of the biopharmaceutical company’s stock valued at $83,684,000 after acquiring an additional 952,193 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Sage Therapeutics by 69.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 811,934 shares of the biopharmaceutical company’s stock worth $15,217,000 after purchasing an additional 333,805 shares during the period. Finally, Fisher Asset Management LLC grew its stake in shares of Sage Therapeutics by 8.1% in the fourth quarter. Fisher Asset Management LLC now owns 431,925 shares of the biopharmaceutical company’s stock worth $9,360,000 after purchasing an additional 32,306 shares during the last quarter. 99.22% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on SAGE. HC Wainwright reiterated a “neutral” rating and issued a $25.00 price objective on shares of Sage Therapeutics in a research report on Friday, August 2nd. Needham & Company LLC reissued a “hold” rating on shares of Sage Therapeutics in a research report on Thursday, August 1st. Baird R W raised shares of Sage Therapeutics to a “hold” rating in a research report on Wednesday, May 29th. Truist Financial reduced their price target on shares of Sage Therapeutics from $18.00 to $13.00 and set a “hold” rating on the stock in a research report on Wednesday, August 14th. Finally, Robert W. Baird lowered their price objective on shares of Sage Therapeutics from $15.00 to $13.00 and set a “neutral” rating for the company in a report on Thursday, July 25th. Two equities research analysts have rated the stock with a sell rating, seventeen have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $16.06.

Sage Therapeutics Stock Up 2.7 %

Shares of NASDAQ SAGE opened at $8.41 on Monday. The company has a 50 day moving average of $10.31 and a 200 day moving average of $14.28. Sage Therapeutics, Inc. has a twelve month low of $7.70 and a twelve month high of $28.26. The firm has a market cap of $506.13 million, a P/E ratio of -1.00 and a beta of 0.90.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.68) by ($0.02). Sage Therapeutics had a negative return on equity of 55.87% and a negative net margin of 458.30%. The business had revenue of $8.65 million during the quarter, compared to analysts’ expectations of $8.85 million. During the same quarter in the prior year, the firm earned ($2.68) EPS. The firm’s revenue for the quarter was up 249.8% compared to the same quarter last year. As a group, equities analysts expect that Sage Therapeutics, Inc. will post -6.39 earnings per share for the current fiscal year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.